Brief: Unity Biotechnology, Inc. Reports Q4 And Full Year 2022 Financial Results And Business Updates

Unity Biotechnology

15/03/2023 20:09

March 15 (Reuters) - Unity Biotechnology Inc  UBX.O :
    * UNITY BIOTECHNOLOGY, INC. REPORTS FOURTH QUARTER AND FULL
YEAR
2022 FINANCIAL RESULTS AND BUSINESS UPDATES
    * UBX1325 16- AND 24-WEEK SAFETY AND EFFICACY DATA FROM
PHASE 2
ENVISION WET AMD STUDY EXPECTED BY END OF MARCH 2023
    * UBX1325 48-WEEK SAFETY AND EFFICACY DATA FROM PHASE 2
BEHOLD DME
STUDY EXPECTED IN Q2 OF 2023
    * TIE2/VEGF BISPECIFIC PRECLINICAL DATA TO SUPPORT SELECTION
OF
DEVELOPMENT CANDIDATE EXPECTED BY END OF 2023
    * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED
$94.8
MILLION AS OF DECEMBER 31, 2022
    * QTRLY LOSS PER SHARE $1.00
    * Q4 EARNINGS PER SHARE VIEW $-1.05 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX6NtWs 
Further company coverage:  UBX.O 

 ((Reuters.Briefs@thomsonreuters.com;))